192 related articles for article (PubMed ID: 35799022)
21. Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.
Xu YS; Xiang J; Lin SJ
Purinergic Signal; 2024 May; ():. PubMed ID: 38771429
[TBL] [Abstract][Full Text] [Related]
22. Research Progress in the Relationship Between P2X7R and Cervical Cancer.
Tang Y; Qiao C; Li Q; Zhu X; Zhao R; Peng X
Reprod Sci; 2023 Mar; 30(3):823-834. PubMed ID: 35799022
[TBL] [Abstract][Full Text] [Related]
23. The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
Li Q; Zhu X; Song W; Peng X; Zhao R
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2731-2741. PubMed ID: 32892231
[TBL] [Abstract][Full Text] [Related]
24. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties.
Zhang WJ; Hu CG; Zhu ZM; Luo HL
Biomed Pharmacother; 2020 May; 125():109844. PubMed ID: 32004973
[TBL] [Abstract][Full Text] [Related]
25. P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells.
Han Y; Bai C; He XM; Ren QL
Purinergic Signal; 2023 Mar; 19(1):145-153. PubMed ID: 35235139
[TBL] [Abstract][Full Text] [Related]
26. Purinergic P2X7 receptor as a potential therapeutic target in depression.
Qi W; Jin X; Guan W
Biochem Pharmacol; 2024 Jan; 219():115959. PubMed ID: 38052270
[TBL] [Abstract][Full Text] [Related]
27. Progress in the relationship between P2X7R and colorectal cancer.
Bai X; Li X; Qiao C; Tang Y; Zhao R; Peng X
Mol Biol Rep; 2023 Feb; 50(2):1687-1699. PubMed ID: 36417079
[TBL] [Abstract][Full Text] [Related]
28. The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.
Han S; Suzuki-Kerr H; Vlajkovic SM; Thorne PR
Purinergic Signal; 2022 Dec; 18(4):435-450. PubMed ID: 36173587
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory profile in cervical cancer: influence of purinergic signaling and possible therapeutic targets.
Franciosi MLM; do Carmo TIT; Zanini D; Cardoso AM
Inflamm Res; 2022 Jun; 71(5-6):555-564. PubMed ID: 35376994
[TBL] [Abstract][Full Text] [Related]
30. Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation.
Wang M; Li XZ; Zhang MX; Ye QY; Chen YX; Chang X
Front Oncol; 2021; 11():738534. PubMed ID: 34692516
[TBL] [Abstract][Full Text] [Related]
31. Atractylenolides (I, II, and III): a review of their pharmacology and pharmacokinetics.
Deng M; Chen H; Long J; Song J; Xie L; Li X
Arch Pharm Res; 2021 Jul; 44(7):633-654. PubMed ID: 34269984
[TBL] [Abstract][Full Text] [Related]
32. Autocrine and paracrine purinergic signaling in the most lethal types of cancer.
Reyna-Jeldes M; Díaz-Muñoz M; Madariaga JA; Coddou C; Vázquez-Cuevas FG
Purinergic Signal; 2021 Sep; 17(3):345-370. PubMed ID: 33982134
[TBL] [Abstract][Full Text] [Related]
33. A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor.
Zhang Y; Li F; Wang L; Lou Y
Biochem Biophys Res Commun; 2021 Jun; 558():147-153. PubMed ID: 33915328
[TBL] [Abstract][Full Text] [Related]
34. PI3K/Akt/GSK-3β signal pathway is involved in P2X7 receptor-induced proliferation and EMT of colorectal cancer cells.
Zhang WJ; Luo C; Huang C; Pu FQ; Zhu JF; Zhu ZM
Eur J Pharmacol; 2021 May; 899():174041. PubMed ID: 33737010
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
